Drug Pipeline

Drug Pipeline Market Research Reports

1 . Drug Pipeline Market Research Reports Analysis and Trends

Discovering and bringing new drugs to mainstream commercial market typically takes an average of 10-15 years of research and clinical development efforts. Drug developers need to make sure safe and effective drug available for patient in quick time. The first step is to target the protein available in the patient’s body that is associated with microorganism causing a disease, through tracking of cellular network of proteins an appropriate target for a drug is selected. Through a series of trials, right drug candidate got chosen.
 
According to “NOVARTIS”, bringing a new drug in market takes 14 years of research and cost around USD 2 billion, 10K+ clinical trials out of these, one leads to successful drug development.
Title Published Pages Price
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 871 USD 2,500.00
Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 35 USD 2,000.00
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 116 USD 3,500.00
Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 50 USD 2,000.00
Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 510 USD 2,500.00
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 70 USD 3,500.00
Bone Metastasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 98 USD 2,000.00
Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 112 USD 2,000.00
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 137 USD 3,500.00
Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 81 USD 2,000.00
Keratitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 110 USD 2,000.00
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 120 USD 3,500.00
Inclusion Body Myositis (IBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 104 USD 2,000.00
Allergic Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 77 USD 2,000.00
Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 51 USD 2,000.00
Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 149 USD 2,000.00
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 69 USD 3,500.00
Ureter Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 150 USD 2,000.00
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 218 USD 2,000.00
Chikungunya Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 111 USD 2,000.00
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 56 USD 3,500.00
Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 47 USD 2,000.00
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 580 USD 2,500.00
Rotavirus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 66 USD 2,000.00
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 37 USD 3,500.00
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 4115 USD 2,500.00
Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 243 USD 2,500.00
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 151 USD 3,500.00
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 1834 USD 2,500.00
Asthma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 814 USD 2,500.00
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 78 USD 3,500.00
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 74 USD 2,000.00
Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 541 USD 2,500.00
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 68 USD 3,500.00
Essential Thrombocythemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 60 USD 2,000.00
Optic Neuritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 63 USD 2,000.00
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 161 USD 3,500.00
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Aug 30 2022 51 USD 2,000.00
Chronic Urticaria or Hives Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 118 USD 2,000.00
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 84 USD 3,500.00
Acinetobacter Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 173 USD 2,000.00
Binge Eating Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 53 USD 2,000.00
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 65 USD 3,500.00
Sickle Cell Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 277 USD 2,500.00
Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 110 USD 2,000.00
Adenosine Receptor A3 (ADORA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 63 USD 3,500.00
Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 394 USD 2,500.00
Guillain-Barre Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 83 USD 2,000.00
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 54 USD 3,500.00
Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Jul 29 2022 109 USD 2,000.00

Clients Who Trust Us

Market Research Reports Inc. Customers

Need tailor made market research solution? We can help you with that too.

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected